阿尼帕米(Anipamil)是新合成的维拉帕米类钙拮抗剂。据临床前和Ⅰ期临床研究,与维拉帕米不同的是半减期较长,首过效应低,血管保护作用强,治疗剂量对房室结无影响,实验剂量不影响心率。本文主要研究3个不同剂量Anipamil的抗高血压作用。 121例高血压病人(Ⅰ～Ⅱ期)在17个康复中心进行了开放研究,应用安慰剂7天 Anipamil is a newly synthesized verapamil calcium antagonist. According to preclinical and phase I clinical studies, different from verapamil is the long half-period reduction, the first pass effect is low, the role of vascular protection, the treatment dose has no effect on atrioventricular node, the experimental dose does not affect the heart rate. This article studies the antihypertensive effects of Anipamil at three different doses. A total of 121 hypertensive patients (stage I-II) underwent an open-label study in 17 rehabilitation centers with placebo for 7 days